GSD type III (Cori disease)

Pathophysiology - The Branching Point Problem

• Primary Defect: Deficiency of the debranching enzyme, amylo-α-1,6-glucosidase.
• Mechanism: Glycogen phosphorylase shortens linear chains to within 4 glucose units of a branch point. The debranching enzyme is then required to remove the branches.
• Metabolic Block: With a defective debranching enzyme, glycogenolysis halts. This results in the accumulation of partially degraded glycogen with short outer chains, a structure known as limit dextrin.

⭐ Gluconeogenesis remains intact, distinguishing it from GSD Type I and explaining the milder, fasting hypoglycemia.

Clinical Presentation - Muscle, Liver & Sugar Low

• Early Childhood Onset:

  • Hepatomegaly: Often massive, but typically improves with age.
  • Hypoglycemia: Mild, ketotic fasting hypoglycemia. Milder than GSD I.
  • Muscle Weakness: Hypotonia and myopathy are common. Can affect the heart (cardiomyopathy).
  • Growth: Failure to thrive and short stature.

• Progression with Age:

  • Liver size tends to normalize around puberty.
  • Muscle weakness is progressive, and cardiomyopathy can worsen, becoming the primary concern in adults.

⭐ Distinguishing from GSD Type I: Blood lactate and uric acid levels are typically normal, as gluconeogenesis is intact.

📌 Mnemonic: Think of a Corvette car with a weak engine (myopathy) and needs a special fuel (no hypoglycemia on normal diet), but the Liver (L) gets better over time.

Diagnosis - Unmasking Cori

• Initial Labs:

  • Fasting hypoglycemia with ketosis.
  • Hyperlipidemia.
  • ↑ Liver transaminases (AST, ALT).
  • Normal blood lactate and uric acid levels (key differentiator from GSD I).
  • ↑ Creatine kinase (CK) suggests muscle involvement (GSD IIIa).

• Glucagon Stimulation Test:

  • Fed state: Normal hyperglycemic response.
  • Fasting state: Blunted response (no rise in blood glucose).

⭐ A key finding is the presence of glycogen with abnormally short outer chains (limit dextrin) on liver biopsy, a direct result of the debranching enzyme deficiency.

• Confirmatory Testing:
  • Enzyme Assay: Deficient amylo-1,6-glucosidase activity in leukocytes or fibroblasts.
  • Genetic Testing: Identifies mutations in the AGL gene.

Management - The Diet Fix

• Primary Goal: Maintain euglycemia, prevent hypoglycemia (especially nocturnal), and support normal growth.
• Dietary Strategy:
  • Frequent, small meals with a high-protein content.
  • Overnight/between-meal uncooked cornstarch (UCCS) supplementation.
    • Provides a slow, steady release of glucose.
    • Typical dosing is every 4-6 hours.
  • Avoidance of high-sugar foods; restriction of sucrose and fructose.

⭐ A high-protein diet is critical. It provides a constant source of amino acids (e.g., alanine) as substrates for gluconeogenesis, creating an alternative route for glucose production that bypasses the defective debranching enzyme.

• Caused by a deficiency in amylo-α-1,6-glucosidase, the debranching enzyme, leading to glycogenolysis failure.
• Results in the accumulation of limit dextrin-like structures-abnormal glycogen with short outer chains.
• Key features include hepatomegaly, ketotic hypoglycemia, hyperlipidemia, growth retardation, and muscle weakness.
• Unlike GSD I, gluconeogenesis is intact, so blood lactate levels are normal.
• Presents as a milder form of von Gierke disease but with significant muscle involvement and potential cardiomyopathy.